UNSPSC 51382301: Dipyrocetyl

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C11H10O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EF5UVE254C, chemically known as 2,3-dihydroxybenzoic acid diacetate but generally known as dipyrocetyl, which bears US NIH Compound Identifier 68093. European Medicines Agency schedules Dipyrocetyl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07231MIG.

UNSPSC 51382301 Dipyrocetyl, a Commodity code, shows limited and misaligned recent state and local procurement activity. The three opportunities posted between January and June 2026 involve naloxone and drug deactivation systems, a therapeutic pharmacy initiative focused on direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products — none of which align directly with dipyrocetyl procurement. The code shows little evidence of active state and local demand for dipyrocetyl specifically; the opportunities tagged to this code appear to reflect broader pharmaceutical and public health purchasing rather than procurement of this particular chemical compound.

Activity is dispersed across Florida, Texas, and Minnesota. Seminole County, Florida issued an IFB (Solicitation Number IFB60459723LAS) on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (note the inconsistency in posted and due dates in the source). The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026 exploring direct-to-manufacturer prescription programs. The Minnesota Department of Administration's Office of State Procurement, administering the Multistate Cooperative Purchasing Alliance (MMCAP), issued an RFP (Solicitation Number S1070000015802) with a response deadline of March 26, 2026 for generic pharmaceuticals and OTC products across Minnesota, Oregon, and other participating jurisdictions. The code does not show substantive recent activity aligned with dipyrocetyl procurement; businesses evaluating this code should verify whether their product offerings match actual issuing-body demand before investing in pursuit.